Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir for HIV Pre-exposure Prophylaxis (PURPOSE 365)
NCT07047716Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenacapavir in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Jul 2025; status: active, not recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07047716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047716.